銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

The allotment status for the ?30.24 crore Avience Biomedicals IPO is expected to be announced today, June 23, 2026. Investors will be able to verify their IPO allotment through the official channels, including the websites of the NSE and the IPO registrar, Skyline Financial Services Limited.?
Following the completion of the allotment process, the shares are expected to be listed on the NSE Emerge platform on June 25, 2026.
[June 22, 2026, 7:00 PM]
|
Category? |
Subscription (times) |
|
Qualified Institutional Buyers (QIBs) |
196.77x |
|
Non-Institutional Investors (NIIs) |
597.23x |
|
Retail Individual Investors (RIIs) |
401.36x |
|
Total? |
385.32x |
Incorporated in 2019, Avience Biomedicals Limited is engaged in manufacturing in vitro diagnostic (IVD) products, diagnostic kits, and medical devices.?
Based in Noida, Uttar Pradesh, the company offers products such as rapid test kits, serology products, biochemistry analysers, and reagents, serving hospitals, laboratories, research centres, and healthcare institutions across India and overseas.
In addition to manufacturing, it also trades and distributes medical equipment. Avience Biomedicals focuses on providing affordable, high-quality diagnostic solutions while expanding its product portfolio and market presence.
Financially, total income stood at ?41.94 crore for the ten months ended January 2026, compared to ?45.97 crore in FY25 and ?24.37 crore in FY24. Profit after tax (PAT) stood at ?5.74 crore during the period, while EBITDA was ?10.34 crore, compared with ?7.23 crore and ?11.41 crore, respectively, in FY25.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.